Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Ironwood Enters into Definitive Agreement to Acquire VectivBio, a Clinical-Stage Biotech Company Pioneering Novel Treatments for Severe Rare Gastrointestinal Diseases

    May 26, 2023

    India as a Quad-led biomanufacturing hub

    May 25, 2023

    Manappuram Finance, Rossari Biotech shares trade ex-dividend today

    May 24, 2023
    Facebook Twitter Instagram
    Your Biotech
    • Bio Technology

      Ironwood Enters into Definitive Agreement to Acquire VectivBio, a Clinical-Stage Biotech Company Pioneering Novel Treatments for Severe Rare Gastrointestinal Diseases

      May 26, 2023

      India as a Quad-led biomanufacturing hub

      May 25, 2023

      Manappuram Finance, Rossari Biotech shares trade ex-dividend today

      May 24, 2023

      Scottish Biotech ILC Therapeutics Signs R&D Partnership With Dechra Pharmaceuticals PLC

      May 23, 2023

      Israeli biotech phenom puts death knell on cancer

      May 22, 2023
    • Pharmaceutical

      Pharma company owner duped of ₹1.1 crore

      November 11, 2022

      Novavax cuts full-year revenue forecast again amid weak demand

      November 10, 2022

      Aurobindo units recall products in US market for manufacturing issues

      November 9, 2022

      AASLD 2022 | Ascentage Pharma Releases Phase I Results of IAP Antagonist APG-1387 in an Oral Report Showing Potential for Functionally Curing CHB

      November 8, 2022

      Trade Spotlight | What should you do with Amara Raja, Sun Pharma Advanced Research, Poly Medicure on Monday?

      November 7, 2022
    Your Biotech
    Home»Bio Technology»U.S. FDA warns of ADHD drug Adderall shortage on Teva manufacturing delays
    Bio Technology

    U.S. FDA warns of ADHD drug Adderall shortage on Teva manufacturing delays

    yourbiotechBy yourbiotechOctober 12, 2022No Comments1 Min Read
    Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp VKontakte Email
    Share
    Facebook Twitter LinkedIn Pinterest Email

    he U.S. Food and Drug Administration said on Wednesday there was a shortage of Adderall, a treatment for attention deficit hyperactivity disorder, following intermittent manufacturing delays at Teva Pharmaceutical Industries Ltd (TEVA.TA).

    U.S.-listed shares of Israel-based Teva were down 1.5% at $7.95 in trading after the bell.

    Adderall is an FDA-approved prescription drug made of two stimulants amphetamine and dextroamphetamine.

    Other manufacturers continue to produce amphetamine mixed salts, but there is not sufficient supply to continue to meet U.S. market demand through those producers, the U.S. health regulator said.

    According to the FDA’s website, supply recovery for different doses and forms of the drug ranges from October 2022 to March 2023.

    “It is possible that some people may encounter a backorder (intermittently) based on timing and high demand, but these are only temporary … and we expect inventory recovery in the coming months,” Teva said on Wednesday.

    Share. Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    Previous ArticleSVA FINAL DEADLINE NOTICE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Sinovac Biotech Ltd. Investors to Secure Counsel Before Important October 17 Deadline in Securities Class Action Against 1Globe Capital LLC and Certain of its Officers – SVA
    Next Article New initiative will calculate carbon footprint of clinical trials
    yourbiotech
    • Website

    Related Posts

    Ironwood Enters into Definitive Agreement to Acquire VectivBio, a Clinical-Stage Biotech Company Pioneering Novel Treatments for Severe Rare Gastrointestinal Diseases

    May 26, 2023

    India as a Quad-led biomanufacturing hub

    May 25, 2023

    Manappuram Finance, Rossari Biotech shares trade ex-dividend today

    May 24, 2023

    Scottish Biotech ILC Therapeutics Signs R&D Partnership With Dechra Pharmaceuticals PLC

    May 23, 2023

    Leave A Reply Cancel Reply

    Our Picks

    Subscribe to Updates

    Get the latest creative news from SmartMag about art & design.

    About Us
    About Us

    We provide a wide range of customized, integrated B2B and B2C digital marketing services solutions that are ideal for your business.

    We're accepting new partnerships right now.

    Email Us: info@yourmartech.com
    Contact: +1-530-518-1420

    Our Brands
    • Your Martech
    • Your HR Tech
    • Your Fin Tech
    • Your Revenue
    • Your Info Tech
    • Your POS Tech
    • Your Health Tech
    SUBSCRIBE NOW
    Loading
    LinkedIn
    • Privacy Policy
    © 2022 Vigarbiz Inc. Designed by Vigarbiz Media

    Type above and press Enter to search. Press Esc to cancel.